SCHEMBL17899450

SCHEMBL17899450

Cc1cc(C(F)(F)F)ccc1CC(=O)O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 4/20 0.72
RXRB P28702 3/20 0.72
RXRG P48443 2/20 0.72
NR1H4 Q96RI1 1/20 0.54
AGBL2 Q5U5Z8 1/20 0.53
PPARD Q03181 1/20 0.47
POLQ O75417 2/20 0.47
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46
PTGDR2 Q9Y5Y4 2/20 0.46
DAO P14920 1/20 0.46
NPSR1 Q6W5P4 1/20 0.44
SRC P12931 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.43
NR1H2 P55055 1/20 0.43
NR1H3 Q13133 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20575945 0.88 RXRA (0.57) RXRARXRBRXRGNR1H4AGBL2
SCHEMBL30120956 0.88 RXRA (0.57) RXRARXRBRXRGNR1H4AGBL2
SCHEMBL14060046 0.86 RXRA (0.55) RXRARXRBRXRGNR1H4AGBL2
SCHEMBL8566067 0.84 RXRA (0.54) RXRARXRBRXRGNR1H4AGBL2
SCHEMBL8580573 0.84 RXRA (0.71) RXRARXRBRXRGNR1H4NPSR1
SCHEMBL3135089 0.84 RXRA (0.53) RXRARXRBRXRGAGBL2POLQ
SCHEMBL30716953 0.82 POLQ (0.61) RXRARXRBRXRGPOLQPSEN1
SCHEMBL3741058 0.82 POLQ (0.61) RXRARXRBRXRGPOLQPSEN1
SCHEMBL512428 0.82 IDO1 (0.51) RXRARXRBRXRGAGBL2POLQ
SCHEMBL30530542 0.82 IDO1 (0.51) RXRARXRBRXRGAGBL2POLQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
US-20160193191-A1 ANTAGONISTS OF CHEMOKINE RECEPTORS CHEMOCENTRYX, INC. 2016-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160193191-A1 ANTAGONISTS OF CHEMOKINE RECEPTORS CCR1, CCR3, CCR2 RXRA 263/4885RXRB 250/4885RXRG 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.